|
Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Begins randomised, open-label, active-controlled phase II/III trial of fruquintinib combination with sintilimab in China. The trial will explore the combination as a second-line treatment for locally advanced or metastatic renal cell carcinoma - the most common type of kidney cancer. The first patient in China received the dose on Thursday, it says.
"Fruquintinib is a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis [the formation of new blood vessels]. Fruquintinib was designed to improve kinase selectivity to minimize off-target toxicities, improve tolerability and provide more consistent target coverage," Hutchmed explains.
Current stock price: 143.00 pence, down 2.7% on Thursday in London
12-month change: down 69%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
